This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kristiansen, G. Articles by Hauptmann, S. Search for Related Content PubMed PubMed Citation Articles by Kristiansen, G. Articles by Hauptmann, S.

(American Journal of Pathology. 2002;161:1215-1221.)
© 2002 American Society for Investigative Pathology

Regular Articles

CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival

Glen Kristiansen^*, Carsten Denkert^*, Karsten Schlüns^*, Edgar Dahl, Christian Pilarsky and Steffen Hauptmann^*

From the Institute of Pathology,^* Charité Hospital, Berlin; and MetaGen Pharmaceuticals , Berlin, Germany

CD24 is a small heavily glycosylated glycosylphosphatidylinositol-linked cell surface protein, which is expressed in hematological malignancies as well as in a large variety of solid tumors. Very recently its expression in ovarian cancer has been found on RNA level by chip analysis. We evaluated CD24 protein expression by immunohistochemistry in 9 normal ovaries and 69 epithelial ovarian tumors (5 adenomas, 8 borderline tumors, and 56 carcinomas) with known follow-up data. Surface epithelium of normal ovaries as well as adenomas did not express CD24. In borderline tumors CD24 was expressed in membrane in 75% of cases, whereas cytoplasmic expression was detected in only one of nine cases. In invasive ovarian carcinomas, a membranous expression was detected in 84% and a cytoplasmic expression in 59% of cases. In univariate survival analysis of all invasive ovarian carcinomas, a highly significant association of increased cytoplasmic CD24 expression with shortened patient survival (mean 98 months versus 37 months, P = 0.0002, log rank test) was demonstrated. Other significant prognostic parameters were International Federation of Gynecology and Obstetrics (FIGO) stage, Silverberg grade, patient age, undifferentiated histological type, and metastatic disease. We did not detect a significant correlation of CD24 with these clinicopathological parameters. In multivariate analysis, only CD24 and FIGO stage were independent prognostic parameters. Our data suggest that the expression of CD24 as detected by immunohistochemistry is a new independent molecular marker for shortened survival time of patients with epithelial ovarian carcinomas.

This article has been cited by other articles:

				M A H Ahmed, A Al-Attar, J Kim, N F S Watson, J H Scholefield, L G Durrant, and M Ilyas CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer J. Clin. Pathol., December 1, 2009; 62(12): 1117 - 1122. [Abstract] [Full Text] [PDF]

				E. Sagiv, A. Starr, U. Rozovski, R. Khosravi, P. Altevogt, T. Wang, and N. Arber Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA Cancer Res., April 15, 2008; 68(8): 2803 - 2812. [Abstract] [Full Text] [PDF]

				H. G. Woo, E. S. Park, J. H. Cheon, J. H. Kim, J.-S. Lee, B. J. Park, W. Kim, S. C. Park, Y. J. Chung, B. G. Kim, et al. Gene Expression-Based Recurrence Prediction of Hepatitis B Virus-Related Human Hepatocellular Carcinoma Clin. Cancer Res., April 1, 2008; 14(7): 2056 - 2064. [Abstract] [Full Text] [PDF]

				B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950. [Abstract] [Full Text] [PDF]

				S. Assou, T. Anahory, V. Pantesco, T. Le Carrour, F. Pellestor, B. Klein, L. Reyftmann, H. Dechaud, J. De Vos, and S. Hamamah The human cumulus-oocyte complex gene-expression profile Hum. Reprod., July 1, 2006; 21(7): 1705 - 1719. [Abstract] [Full Text] [PDF]

				A. Ostapkowicz, K. Inai, L. Smith, S. Kreda, and J. Spychala Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. Mol. Cancer Ther., February 1, 2006; 5(2): 238 - 245. [Abstract] [Full Text] [PDF]

				H. Schabath, S. Runz, S. Joumaa, and P. Altevogt CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells J. Cell Sci., January 15, 2006; 119(2): 314 - 325. [Abstract] [Full Text] [PDF]

				P. Baumann, N. Cremers, F. Kroese, G. Orend, R. Chiquet-Ehrismann, T. Uede, H. Yagita, and J. P. Sleeman CD24 Expression Causes the Acquisition of Multiple Cellular Properties Associated with Tumor Growth and Metastasis Cancer Res., December 1, 2005; 65(23): 10783 - 10793. [Abstract] [Full Text] [PDF]

				D. A. Ferguson, M. R. Muenster, Q. Zang, J. A. Spencer, J. J. Schageman, Y. Lian, H. R. Garner, R. B. Gaynor, J. W. Huff, A. Pertsemlidis, et al. Selective Identification of Secreted and Transmembrane Breast Cancer Markers using Escherichia coli Ampicillin Secretion Trap Cancer Res., September 15, 2005; 65(18): 8209 - 8217. [Abstract] [Full Text] [PDF]

				W. Weichert, C. Denkert, M. Burkhardt, T. Gansukh, J. Bellach, P. Altevogt, M. Dietel, and G. Kristiansen Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival Clin. Cancer Res., September 15, 2005; 11(18): 6574 - 6581. [Abstract] [Full Text] [PDF]

				R. Fiume, I. Faenza, A. Matteucci, A. Astolfi, M. Vitale, A. M. Martelli, and L. Cocco Nuclear Phospholipase C {beta}1 (PLC{beta}1) Affects CD24 Expression in Murine Erythroleukemia Cells J. Biol. Chem., June 24, 2005; 280(25): 24221 - 24226. [Abstract] [Full Text] [PDF]

				G. J. Gordon, G. N. Rockwell, P. A. Godfrey, R. V. Jensen, J. N. Glickman, B. Y. Yeap, W. G. Richards, D. J. Sugarbaker, and R. Bueno Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma Clin. Cancer Res., June 15, 2005; 11(12): 4406 - 4414. [Abstract] [Full Text] [PDF]

				Y. van Hensbergen, H. J. Broxterman, S. Rana, P. J. van Diest, M. C. A. Duyndam, K. Hoekman, H. M. Pinedo, and E. Boven Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts Clin. Cancer Res., February 1, 2004; 10(3): 1180 - 1191. [Abstract] [Full Text] [PDF]

				E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms Clin. Cancer Res., December 15, 2003; 9(17): 6453 - 6460. [Abstract] [Full Text] [PDF]

				G. Kristiansen, K.-J. Winzer, E. Mayordomo, J. Bellach, K. Schluns, C. Denkert, E. Dahl, C. Pilarsky, P. Altevogt, H. Guski, et al. CD24 Expression Is a New Prognostic Marker in Breast Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4906 - 4913. [Abstract] [Full Text] [PDF]

				K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis PNAS, October 14, 2003; 100(21): 12343 - 12348. [Abstract] [Full Text] [PDF]

				K. G. Kohlgraf, A. J. Gawron, M. Higashi, J. L. Meza, M. D. Burdick, S. Kitajima, D. L. Kelly, T. C. Caffrey, and M. A. Hollingsworth Contribution of the MUC1 Tandem Repeat and Cytoplasmic Tail to Invasive and Metastatic Properties of a Pancreatic Cancer Cell Line Cancer Res., August 15, 2003; 63(16): 5011 - 5020. [Abstract] [Full Text] [PDF]